###### Key messages

-   Therapeutic strategies for non-small-cell lung cancer (NSCLC) have focused on next-generation EGFR-TKIs and immunotherapies.

-   Rebiopsy is required to evaluate the T790M mutation or programmed cell death-ligand 1 expression.

-   The aim of this study was to assess the feasibility and safety of transbronchial biopsy (TBB) in patients with NSCLC relapse.

-   We demonstrated that TBB for rebiopsy has a high diagnostic yield without severe complications.

-   The diagnostic yield was not associated with patient background and treatment history.

Introduction {#s1}
============

Non-small-cell lung cancer (NSCLC) is the leading cause of death worldwide due to cancer.[@R1] Transbronchial biopsy (TBB) using a flexible bronchoscope has been commonly used for establishing a diagnosis of lung cancer, having a more favourable safety profile than transthoracic needle aspiration or surgical procedures.[@R2] Although the diagnostic yield of TBB has not been satisfactory, especially for small peripheral lesions, recent technical advances have improved its diagnostic accuracy.[@R4]

Therapeutic strategies for NSCLC over the past few decades have focused on overcoming resistance to molecular targeted therapies and development of immunotherapies.[@R5] It has been suggested that expression of programmed cell death-ligand 1 (PD-L1) in tumours may predict a favourable response to immune checkpoint inhibitors.[@R13] [@R14] In order to evaluate the mechanisms of resistance to molecular targeted therapies, immunostaining for PD-L1 is necessary using tumour samples obtained after disease progression. Rebiopsy is performed for this purpose, and TBB seems to be the safest method for doing so, except for cases of skin, muscle or superficial lymph node metastasis. However, the utility of TBB as a rebiopsy method and the impact of previous treatment on its diagnostic yield are unknown. Here, we retrospectively evaluated the accuracy and safety of TBB as a rebiopsy method in patients with advanced NSCLC that had relapsed after systemic chemotherapy, and the factors influencing its diagnostic yield.

Materials and methods {#s2}
=====================

Patients {#s2a}
--------

We retrospectively screened 2126 consecutive patients who underwent bronchoscopy at Kurume University Hospital between January 2012 and June 2016. Among these patients, 109 with advanced NSCLC who underwent TBB for rebiopsy after developing resistance to systemic chemotherapy were enrolled. These patients underwent TBB for enrolment in clinical trials that required rebiopsy, further investigation of tumour mutations, or assessment of whether TKI treatment should be continued. In patients who underwent multiple rebiopsies, the result of the initial rebiopsy was selected. The clinical characteristics of the patients, including age, sex, smoking status, histology, mutational status, tumour size, previous treatment and efficacy of the previous treatment, were recorded. Tumour response was examined by CT and evaluated using the Response Evaluation Criteria for Solid Tumors V.1.0 (RESIST V.1.0).[@R15] The present study was conducted in accordance with the provisions of the Declaration of Helsinki and was approved by the Institutional Review Board of Kurume University Hospital (IRB No. 12029). Informed consent was obtained from the patients.

Procedure of TBB {#s2b}
----------------

For TBB, a conventional flexible bronchoscope (BF-260, P260F, P290 or 1T240 Bronchovideoscope, Olympus, Tokyo, Japan) was used after spraying the pharynx with 2% xylocaine. Procedures were performed under conscious sedation with midazolam. TBB was performed under guidance with a radial ultrasound probe (UM-S20-17S, Olympus, Tokyo, Japan) and a guide sheath kit (K-201, Olympus, Tokyo, Japan) in patients with peripheral pulmonary lesions. A positive diagnostic result obtained by TBB was defined as malignancy determined on the basis of histological features that were adequate for mutational analysis or immunohistochemistry. Severe postprocedural complications were defined as those requiring invasive medical procedures or prolonged hospitalisation.

Statistical analysis {#s2c}
--------------------

Correlations between patient characteristics and the success of rebiopsy were analysed using Fisher\'s exact test for categorical variables. All tests were two-sided, and differences were considered statistically significant at p\<0.05. All of the statistical analyses were conducted using JMP V.10 (SAS Institute, Cary, North Carolina, USA).

Results {#s3}
=======

Patient characteristics {#s3a}
-----------------------

The clinical characteristics of the 109 patients are shown in [table 1](#BMJRESP2016000163TB1){ref-type="table"}. The median age of the patients at the time of rebiopsy was 67 years (range 33--85 years), and 50 of the patients were men. One hundred and one patients had adenocarcinoma, and 59 patients had no smoking history. Sixty-two of the patients had epidermal growth factor receptor (EGFR) mutation, five had anaplastic lymphoma kinase (ALK) rearrangement, and 42 were negative for both EGFR and ALK anomaly. Rebiopsy was performed after first-line treatment in 61 patients, after second-line treatment in 24, and after third-line or further treatment in 24. The mean diameter of the target lesions for rebiopsy was 34.6 mm (range 10--89 mm). Ten patients had lung metastasis that was targeted for rebiopsy. Tumour or bronchial mucosal infiltration was visible on bronchoscopy in 25 patients, and invisible in 84 patients who had only peripheral lung lesions. The overall rate of response to the previous treatment before rebiopsy was 55.0%.

###### 

Patient characteristics

  Patient characteristics    Number   Per cent
  -------------------------- -------- ----------
  Age                                 
   Median                    67       
   Range                     33--85   
  Sex                                 
   Male                      50       45.9
   Female                    59       54.1
  Smoking status                      
   Never                     59       54.1
   Former/current            50       45.9
  Histology                           
   Adenocarcinoma            101      92.7
   Squamous cell carcinoma   8        7.3
  Mutational status                   
   EGFR                      62       56.9
   ALK                       5        4.6
   Wild                      42       38.5
  Pretreatment line                   
   First                     61       56.0
   Second                    24       22.0
   Third or further          24       22.0
  Tumour size (mm)                    
   Mean                      34.6     
   Range                     10--89   

ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor.

Results of rebiopsy and postprocedural complications {#s3b}
----------------------------------------------------

Adequate tumour samples were obtained from 88 patients, giving an overall diagnostic yield of 80.7% ([figure 1](#BMJRESP2016000163F1){ref-type="fig"}A). Among these patients with positive diagnostic results, 64 were analysed by predesigned mutational testing and 24 by immunohistochemistry. In 21 patients, the tumour samples collected were inadequate. Although the pathological features of the specimens suggested possible malignancy in four patients, these samples were inadequate for mutational analysis or immunostaining because of fragmentation or low numbers of cells. Furthermore, one patient had only a necrotic tissue without viable tumour cells ([figure 1](#BMJRESP2016000163F1){ref-type="fig"}B). The specimen from the remaining patients showed normal lung tissue and fibrosis in 13 and 3 patients, respectively ([figure 1](#BMJRESP2016000163F1){ref-type="fig"}C).

![Pathological findings of rebiopsy. (A) Positive diagnostic result, showing tubular adenocarcinoma. (B) Negative diagnostic result, showing necrotic tissue without viable tumour cells. (C) Negative diagnostic result, showing fibrosis and infiltration of inflammatory cells.](bmjresp2016000163f01){#BMJRESP2016000163F1}

Postprocedural complications were observed in 12 cases. Four patients developed transient fever, and haemorrhage during the biopsy, requiring haemostasis, occurred in eight patients. However, none of these events required inpatient hospitalisation or prolongation of existing hospitalisation. There were no cases of pneumothorax or massive haemoptysis.

Association between diagnostic yield and clinicopathological features {#s3c}
---------------------------------------------------------------------

The factors affecting the diagnostic yield of TBB for rebiopsy are shown in [table 2](#BMJRESP2016000163TB2){ref-type="table"}. The diagnostic yield of TBB for mass lesions was significantly higher than that for nodular lesions (≥30 mm: 59 of 65 lesions; 90.1% vs \<30 mm: 29 of 44 lesions; 65.9%, p\<0.01). There was no significant correlation between diagnostic yield and other clinicopathological features including tumour mutational status, previous treatment and efficacy of the previous treatment before rebiopsy.

###### 

Results of rebiopsy and association between diagnostic yield and factors

                               Tissue obtained        
  ---------------------------- ----------------- ---- --------
  Age                                                 
   \<70                        51                13   0.81
   ≥70                         37                8    
  Sex                                                 
   Male                        42                8    0.47
   Female                      46                13   
  Smoking status                                      
   Never                       45                14   0.23
   Former/current              43                7    
  Histology                                           
   Adenocarcinoma              82                19   0.65
   Squamous cell carcinoma     6                 2    
  Mutational status                                   
   EGFR/ALK                    53                14   0.63
   Wild                        35                7    
  Tumour size                                         
   \<30 mm                     29                15   \<0.01
   ≥30 mm                      59                6    
  Rebiopsy site                                       
   Primary                     80                19   1.00
   Metastatic                  8                 2    
  Previous treatment                                  
   Platinum-based                                     
    Received                   63                14   0.79
    Not received               25                7    
   Antiangiogenesis agent                             
    Received                   29                8    0.80
    Not received               59                13   
   Molecular targeting agent                          
    Received                   48                14   0.34
    Not received               40                7    
  Response of last treatment                          
   CR/PR                       50                10   0.47
   SD/PD                       38                11   

ALK, anaplastic lymphoma kinase; CR, complete response; EGFR, epidermal growth factor receptor; PD, progressive disease; PR, partial response; SD, stable disease.

Discussion {#s4}
==========

With the development of new therapeutic strategies for NSCLC, including next-generation EGFR-TKIs or blockade of immune checkpoints with monoclonal antibodies, the importance of rebiopsy has increased.[@R11] Any method for tissue collection in this setting should be reliable and safe. In the present study, we investigated TBB as a method for rebiopsy in patients with advanced NSCLC that had relapsed after systemic chemotherapy. We found that TBB had a high diagnostic yield of 80.7% and was not associated with severe complications. As far as we are aware, no previous study has investigated the utility of TBB for rebiopsy in NSCLC patients, or the factors influencing its diagnostic yield. Some previous studies have investigated the feasibility of rebiopsy in NSCLC patients. Chouaid *et al*[@R16] and Bosc *et al*[@R17] reported that an adequate tissue sample was obtained in 74.4% (61/82) and 89.7% (35/39) of cases, the proportions of patients undergoing TBB for rebiopsy being 52% (43/82) and 28% (11/39), respectively. Yoon *et al*[@R18] reported a diagnostic yield of 80% (75/94) for chest CT-guided transthoracic lung biopsy, with a postprocedural serious complication rate of 14%. Although the present study was limited to only TBB, the diagnostic yield compared favourably with those of previous studies.

Recently, endobronchial ultrasound-guided TBB with a guide sheath (EBUS-GS) has been used to improve the diagnostic yield for small peripheral pulmonary lesions.[@R19] Wang Memoli *et al*[@R27] reported the results of a meta-analysis of diagnostic yield for several bronchoscopy modalities. The pooled diagnostic yield was 70% for all modalities, and the highest diagnostic yield for bronchoscopic evaluation (73.2%) appeared to be associated with the use of EBUS-GS. EBUS-GS-guided TBB was also shown to have a quite favourable safety profile, with a pneumothorax rate of 1.5% and no episodes of severe bleeding. Consistent with previous reports, we found that TBB had a high diagnostic yield, even for small peripheral pulmonary lesions, as long as the tumour was detectable by EBUS-GS ([figure 2](#BMJRESP2016000163F2){ref-type="fig"}). Furthermore, there were no severe complications such as pneumothorax or serious haemorrhage. In comparison with core needle biopsy or surgical biopsy, which have higher accuracy for rebiopsy but are more invasive, TBB is a safer method with equivalent diagnostic ability.

![Successful tissue collection in patients with relapse of EGFR-positive adenocarcinoma after EGFR-TKI treatment. (A) Chest CT demonstrates a nodular lesion 12 mm in diameter in S10 of the left lung. (B) EBUS image shows a hypoechoic nodule with an irregular margin. (C) Transbronchial biopsy of the lesion detected by EBUS. EBUS, endobronchial ultrasound; EGFR, epidermal growth factor receptor.](bmjresp2016000163f02){#BMJRESP2016000163F2}

We initially hypothesised that a dramatic reduction of tumour volume resulting from previous treatment might have a negative impact on the diagnostic yield of TBB. Use of the antiangiogenic agent bevacizumab for non-squamous cell NSCLC and molecular targeting inhibitors for EGFR/ALK-positive NSCLC has yielded relatively high response rates in comparison with conventional systemic chemotherapies.[@R5] [@R28] [@R29] We investigated the association between diagnostic yield and several factors, including the previous treatment regimen or response to the previous treatment before rebiopsy. However, the success of tissue collection by TBB was not associated with tumour mutational status, previous treatment or efficacy of the previous treatment before rebiopsy. Our findings indicated that in a rebiopsy setting, the diagnostic yield and safety profile of TBB are adequate.

This study had several limitations. First, the number of patients included was relatively small. Second, the information was collected retrospectively. Third, the indication of TBB for rebiopsy was determined by individual attending physicians. Also, as TBB was performed for pulmonary lesions considered to have sufficient tissue for biopsy based on CT findings, this may have resulted in selection bias.

In conclusion, we have demonstrated that TBB for rebiopsy of NSCLC that has relapsed after chemotherapy is not associated with severe complications and has a high diagnostic yield, regardless of tumour mutational status, previous treatment or efficacy of the previous treatment before rebiopsy. Our results suggest that TBB is one of the safest and most accurate procedures for rebiopsy, and can yield information useful for decision-making about possible next-line treatment.
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